Today: 19 July 2026
Freedom Holding (FRHC) stock price slips in early New York trade after wild rebound
23 February 2026
1 min read

Freedom Holding (FRHC) stock price slips in early New York trade after wild rebound

New York, Feb 23, 2026, 09:55 EST — Regular session

  • Freedom Holding Corp slipped roughly 1% at the open, giving back a portion of Friday’s 6.8% gain.
  • After tumbling to a 52-week low last week, the stock is now struggling to find its footing.
  • Investors continue to parse a quarterly report that revealed customer numbers up, but insurance premium income coming in weaker.

Freedom Holding Corp shares slipped on Monday, paring part of Friday’s strong bounce with light activity in early trading.

The Nasdaq-listed shares slipped roughly 1.1% to $118.36 as of 9:34 a.m. ET, following a Friday close at $119.65.

Why this matters: February’s seen the stock whip around, and traders haven’t settled the debate—was last week’s rally just a breather, or did it finally carve out a bottom?

Friday was telling. Shares swung between $111.86 and $120.46, ultimately closing up 6.8% for the day. That followed a low of $107.98 just the previous session.

Freedom’s fiscal third-quarter numbers, covering the stretch through Dec. 31, landed with revenue slipping and profit nearly flat. The company saw currencies and derivatives gains helping to counterbalance losses from insurance.

Freedom reported net total revenue of $628.6 million for the quarter, while net income landed at $76.2 million. Diluted earnings per share came in at $1.25.

Insurance weighed heavily. The company reported insurance premiums earned, net of reinsurance, dropped 40% to $106.9 million. Management pointed to a regulatory cap on commissions paid to agents selling policies tied to bank and microfinance loans as the culprit.

Freedom also reported a $45.8 million net gain from foreign exchange operations for the quarter—substantially higher than the same period last year—driven by currency shifts and revaluation. The company posted a $26.5 million net gain on derivatives as well.

The company cited gains in its customer base, reporting brokerage customers at 828,000 as of Dec. 31. Banking customers reached 4.5 million, according to the firm.

Still, risks linger. That regulatory move denting insurance volumes highlights just how abruptly a rule tweak in Freedom’s key markets can show up in revenue. Gains from trading and currencies? Those, too, can flip in a hurry.

No scheduled events appear on the company’s investor relations calendar, so the stock is moving with shifts in risk appetite and any new regulatory news.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • CSL Recovers A$16 Billion in Value, Trails Plasma Sector Gains This Week
    July 19, 2026, 3:25 PM EDT. CSL Limited (ASX:CSL) finished July 17 at A$123.32, rising 1.12% on the session and 0.35% for the week, recovering 37% from its 52-week low at A$90 and regaining roughly A$16 billion in valuation. However, CSL underperformed plasma specialists Grifols SA (+1.95%) and Takeda Pharmaceutical (+2.26%) in weekly movement. Trading volume for CSL on Friday came in 14% under its average as 1.62 million shares changed hands. The full-year financial results are due August 18. Still 55% beneath its 52-week peak, CSL's market value stands at A$59.06 billion. The group forecasts FY26 revenues near US$15.2 billion and NPATA of about US$3.1 billion, while a US$5 billion impairment remains subject to audit and board sign-off.
Why CrowdStrike stock price (CRWD) slid 8% — and what investors watch next week
Previous Story

Why CrowdStrike stock price (CRWD) slid 8% — and what investors watch next week

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop